CIBA $425 MIL. DEBT GUARANTEE PROVIDES CHIRON WITH POWER TO ACQUIRE; CHIRON HAS BROAD TECHNOLOGY INTERESTS ALREADY; $2.1 BIL. DEAL BEGINS WITH $1.4 BIL. TENDER
Chiron's $2.1 bil. partnership with Ciba simultaneously takes the biotech firm out of play as a takeover candidate and strengthens its position as a potential purchaser of technology.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth